Nature · 2014 · 5.3K citations · 28 references
MedicineImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyAntitumor T Cell ResponsesCancer ImmunotherapyCheckpoint Inhibitor TherapyImmune Checkpoint InhibitorsImmuno-oncology BiomarkersTherapy Response AssessmentCheckpoint Inhibitor AntibodiesPd-l1 BlockadeProgrammed Cell Death Ligand 1 InhibitionProgrammed Cell Death Protein 1 (Pd-1) PathwayProgrammed Cell Death Protein 1 InhibitorsProgrammed Death-ligand 1 BiomarkerProgrammed Death-ligand 1 Inhibitors
28
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi, Steven O’Day, David F. McDermott et al. · New England Journal of Medicine · 2010 · 15.2K citations · Full text
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer et al. · New England Journal of Medicine · 2012 · 12.7K citations · Full text
Life Sciences, Immunology, Oncology +17